

A Case Whose Intermittent Claudication Disappeared After Weight Reduction

Katsuhiko Toda*

*Corresponding author

730-0044, Japan, Tel: +81 82 543 6688; Fax: +81 82 543 6689; E-mail: goutattack@yahoo.co.jp

Received date: June 05, 2018; **Accepted date:** June 11, 2018; **Published date:** June 12, 2018

Copyright: © 2018 Toda K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

A 58-year-old male (162.1 cm, 76.8 kg, body mass index 29.2) suffered from intermittent claudication. At the initial visit, walking 10-100 meters caused pain in lateral part of the right lower limb, resulting in inability to walk. X-ray showed mild forward slip of the fifth lumbar vertebra, however, MRI did not show narrowing of the lumbar canal. He could walk at least 1 km without pausing with Neurotropin®. If he failed to take Neurotropin®, he suffered from pain of the right lower limb. Four months later, he weighed 71.0 kg. He discontinued Neurotropin®, however, he did not feel pain during walking.

On February 3, 2018, he weighed 73.8 kg. He could walk at least 1 km without pausing. Four tablets per day Neurotropin were administered.



Figure 2

Weight reduction of approximately 6 kg eliminated intermittent claudication without Neurotropin®. Weight reduction is one of the first-line treatments in obese or overweight patients with (suspected) LCS (or intermittent claudication).

References

1. Toda K (2018) Is pharmacological treatment of pain harmful or beneficial? *J Clin Invest Stud* 1: 1-1.
2. Borstlap AC, van Rooij WJ, Sluzewski M, Leyten AC, Beute G (1995) Reversibility of lumbar epidural lipomatosis in obese patients after weight-reduction diet. *Neuroradiology* 37: 670-673.
3. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Tsaousis CA, et al. (2014) Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature* 514: 181-186.
4. Gul SS, Hamilton AR, Munoz AR, Phupitakphol T, Liu W, et al. (2017) Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. *Appl Physiol Nutr Metab* 42: 77-83.